Skip to main content
We’re here to support you each step of the way
We're here to support you each step of the way

We want to help you or your loved one throughout treatment with TAFINLAR + MEKINIST. Here, you will find educational resources and information about financial aid and our Patient Assistance Now Oncology program (PANO, for short).

Caregiver brochure cover icon

Download our Caregiver’s Brochure

This brochure has essential information about treatment with TAFINLAR + MEKINIST, including disease information, how TAFINLAR + MEKINIST works, how to administer these medications, and potential side effects.
Download
Divider

Novartis Oncology Universal Co-pay Program

You may be eligible for immediate co-pay savings on your next prescription of TAFINLAR or MEKINIST. 

 

  • Eligible patients with private insurance may pay $0 per month* ($0 per month for a 30-day supply of TAFINLAR and $0 for a 30-day supply of MEKINIST). Co-pay of $0 is only for TAFINLAR and MEKINIST combination therapy

  • Novartis will pay the remaining co-pay, up to $15,000 per calendar year, per product*

Novartis Universal Co-pay Card

*Limitations apply. This offer is only available to patients with private insurance. The program is not available for patients who are enrolled in Medicare, Medicaid, or any other federal or state health care program. Novartis reserves the right to rescind, revoke, or amend this program without notice. For full Terms and Conditions, visit CoPay.NovartisOncology.com or call 1-877-577-7756.

To find out if you are eligible for the Universal Co-pay Program, call 1-877-577-7756 or visit CoPay.NovartisOncology.com.

Divider

Patient Assistance Now Oncology 

Our Patient Assistance Now Oncology (PANO) program was created to assist you with accessing your Novartis medicine(s)—from insurance verification to financial assistance—all through a knowledgeable and supportive call center.

Free Trial and Access Program
With the Free Trial and Access Program, you can receive a free supply of TAFINLAR + MEKINIST for a US Food and Drug Administration–approved indication. The supply can be shipped directly to your home or another convenient location so your child can start treatment immediately. Program rules may vary by product.

Ask your health care professional to help you apply for the PANO Free Trial and Access Program.

Patient Assistance Now Oncology (PANO)

To learn more, call 1-800-282-7630 or visit Patient.NovartisOncology.com.

Important Safety Information

TAFINLAR and MEKINIST may cause serious side effects, including:

Risk of new cancers. TAFINLAR, when used in combination with MEKINIST, may cause a type of skin cancer called cutaneous squamous cell carcinoma, keratoacanthoma, basal cell carcinoma, or melanoma. Talk with your health care provider about your risk for these cancers. Check your skin and tell your health care provider right away about any skin changes, including a new wart, skin sore, or reddish bump that bleeds or does not heal, or a change in size or color of a mole.

Your health care provider should check your skin before you start treatment, and every 2 months while on treatment, to look for any new skin cancers. Your health care provider should continue to check your skin for 6 months after you stop taking TAFINLAR and MEKINIST.

Approved Uses

TAFINLAR and MEKINIST are prescription medicines that can be used in combination to treat people with a type of skin cancer called melanoma:

  • that has spread to other parts of the body (metastatic) or cannot be removed by surgery (unresectable), and

  • that has a certain type of abnormal “BRAF” (V600E or V600K mutation-positive) gene

TAFINLAR and MEKINIST are prescription medicines that can be used in combination to help prevent melanoma that has a certain type of abnormal “BRAF” gene from coming back after the cancer has been removed by surgery.

Click or scroll to see IMPORTANT SAFETY INFORMATION AND APPROVED USES